• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nuvectis Pharma, Inc. - Common Stock (NQ: NVCT )

    7.190 -0.040 (-0.55%)
    Streaming Delayed Price Updated: 3:41 PM EDT, Aug 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 234,516
    Open 7.200
    Bid (Size) 7.070 (1)
    Ask (Size) 7.190 (1)
    Prev. Close 7.230
    Today's Range 6.760 - 7.500
    52wk Range 5.850 - 15.50
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT)
    Via AB Newswire
    Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
    Via AB Newswire

    Performance

    YTD
    -13.27%
    -13.27%
    1 Month
    +6.68%
    +6.68%
    3 Month
    +18.25%
    +18.25%
    6 Month
    +2.27%
    +2.27%
    1 Year
    -51.81%
    -51.81%

    More News

    Read More
    Precision Medicine M&A is Transforming the Future of the Biotech Industry
    Via AB Newswire
    7 Penny Biotech Stocks to Triple Your Investment
    Via InvestorPlace
    Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Recap: Nuvectis Pharma Q3 Earnings
    Via Benzinga
    NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024
    Via InvestorPlace
    Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    5 Healthcare Stocks to Buy for 2024
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Nuvectis Pharma to Present at the 36th Annual Roth Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023
    Via InvestorPlace
    Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.